Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a UnitedHealth stock analysis and talk about the risks and upside potential of UNH stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
27 Jan 2026, 23:58 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do a UnitedHealth stock analysis and talk about the risks and upside potential of UNH stock
Source overview

AI-generated source summary

The stock UNH has experienced a significant drop, trading at 282.26, down 19.76% today. This decline is attributed to several factors including the company's divestitures in international markets, a projected 2% year-over-year revenue decline for 2026, and a $6 billion revenue hit from Medicare's new coding system. The company is shifting focus to profitable growth in its US operations. While the current forward P/E ratio of 16.15 is considered low historically, suggesting potential undervaluation, the company's guidance and market headwinds indicate a bearish short-term outlook. The analysis suggests a potential price target of 250, with a stop-loss at 300.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail